Humulin S (Soluble)

Humulin S (Soluble) is a recombinant human insulin (rDNA) supplied as a solution for injection. It is a short‑acting insulin formulation used in the European market. The product is administered subcutaneously and is available only by prescription. It provides rapid glucose‑lowering effects for people with diabetes mellitus.

Humulin S is indicated for the management of blood glucose in diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other medications.

- Treatment of type 1 diabetes mellitus when basal insulin is combined with rapid‑acting insulin. - Supplemental insulin for type 2 diabetes mellitus patients who require additional glucose control. - Management of post‑prandial hyperglycemia. - Use in insulin‑pump therapy where rapid‑acting insulin is required. - Adjustment of insulin dose during illness, stress, or changes in physical activity.

Humulin S may cause a range of adverse reactions, from mild to severe. Awareness of common and serious events helps patients and clinicians monitor therapy.

Common: - Hypoglycemia (low blood sugar) - Injection site redness, swelling, or itching - Lipodystrophy at injection sites - Mild weight gain - Transient headache

Serious: - Severe hypoglycemia with loss of consciousness - Allergic reactions such as urticaria or angioedema - Anaphylaxis - Persistent edema or heart failure exacerbation - Hypersensitivity leading to eosinophilia

When using Humulin S, several safety considerations should be observed to minimize risks.

- Monitor blood glucose regularly to detect hypoglycemia early. - Adjust doses during pregnancy, illness, or changes in activity level. - Use caution in patients with renal or hepatic impairment. - Educate patients on proper injection technique to avoid lipodystrophy. - Review cardiovascular status in patients with heart failure. - Avoid use in individuals with known hypersensitivity to human insulin.

Humulin S can interact with various medications and substances, influencing its glucose‑lowering effect.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - High‑dose beta‑blockers that may mask hypoglycemia symptoms. - Alcohol excess, which can potentiate hypoglycemia.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise blood glucose and require dose changes. - Thyroid hormones, which can alter insulin sensitivity. - Diuretics, especially thiazides, that may affect glucose control.